Evidence map›Paper›PMID 39052225›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Targeted Mass Spectrometry for Quantification of Receptor Tyrosine Kinase Signaling.

Jeffrey R Whiteaker, Lei Zhao, Jacob J Kennedy, Richard G Ivey, Amanda G Paulovich

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jeffrey R WhiteakerFred Hutchinson Cancer Center, Seattle, WA, USA.
Lei ZhaoFred Hutchinson Cancer Center, Seattle, WA, USA.
Jacob J KennedyFred Hutchinson Cancer Center, Seattle, WA, USA.
Richard G IveyFred Hutchinson Cancer Center, Seattle, WA, USA.
Amanda G PaulovichFred Hutchinson Cancer Center, Seattle, WA, USA. apaulovi@fredhutch.org.

Funding

Proteogenomic Studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefitU01CA214114 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BIRRER, MICHAEL, PAULOVICH, AMANDA G · 2017 to 2021
$8.4M
Clinical translation of a NexGen platform for quantifying protein networks in human biospecimensR01CA235575 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI AMANDA G PAULOVICH · 2019 to 2026
$6.0M
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapiesU01CA271407 · NCI · FRED HUTCHINSON CANCER CENTER · PI Diwakar Davar, AMANDA G PAULOVICH · 2022 to 2026
$5.6M
A proteomics research specialist in developing targeted mass spectrometry methods for quantifying proteins important in cancerR50CA211499 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Jeff Whiteaker · 2016 to 2026
$2.8M
NCI NIH HHS R01 CA235575NCI NIH HHS R50 CA211499NCI NIH HHS U01 CA214114NCI NIH HHS U01 CA271407
6 · The paper itself

Abstract

Targeted proteomics enables sensitive and specific quantification of proteins and post-translational modifications. By coupling peptide immunoaffinity enrichment with targeted mass spectrometry, we have developed the methodology for multiplexed quantification of proteins and phosphosites involved in the RAS/MAPK signaling network. The method uses anti-peptide antibodies to enrich analytes and heavy stable isotope-labeled internal standards, spiked in at known concentrations. The enriched peptides are directly measured by multiple-reaction monitoring (MRM), a well-characterized quantitative mass spectrometry-based method. The analyte (light) peptide response is measured relative to the heavy standard. The method described provides quantitative measurements of phospho-signaling and is generally applicable to other phosphopeptides and sample types.

Indexed as

Mass SpectrometryProteomicsSignal TransductionHumansIsotope LabelingPhosphopeptidesPhosphorylationProtein Processing, Post-TranslationalReceptor Protein-Tyrosine KinasesTandem Mass SpectrometryPhosphopeptidesReceptor Protein-Tyrosine KinasesLC–MSMultiplexPhospho-signalingQuantitationRAS/MAPKTargeted proteomics

Identifiers

PMID39052225
PMCPMC11995868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.